NodThera
Small molecule drug candidate to treat inflammatory diseases, as well as other drugs for neurodegenerative diseases and cancers.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 -7.5x EV/EBITDA | round | |
* | N/A | N/A | Series B |
| Total Funding | 000k | ||
| GBP | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
NodThera is a biotechnology company focused on developing innovative therapeutics targeting the NLRP3 inflammasome, a protein complex involved in the body's inflammatory response. The company operates in the pharmaceutical and healthcare market, serving patients suffering from chronic inflammatory diseases. NodThera's business model revolves around its proprietary drug discovery platform, which leverages advanced medicinal chemistry to create next-generation small molecule inhibitors. These inhibitors are designed for high potency, optimal pharmacokinetics (how the drug moves through the body), and effective tissue penetration. The company generates revenue through the development and potential commercialization of its drug candidates, as well as through partnerships and collaborations with other pharmaceutical companies. NodThera's lead candidate, NT 0167, is currently in Phase 1 clinical trials, assessing its safety and efficacy. The company is also progressing a pipeline of other NLRP3 inhibitors, including those capable of crossing the blood-brain barrier to treat neurological conditions.
Keywords: NLRP3 inflammasome, chronic diseases, drug discovery, small molecules, biotechnology, pharmacokinetics, Phase 1 clinical trial, medicinal chemistry, inflammation, neurological conditions.